Search by Abstract Number Results

Abstract Number: 0952 • ACR Convergence 2024
Single Cell RNA-seq of Scleroderma-associated Interstitial Lung Disease Lung Explants Reveals an Active, Cytotoxic Natural Killer Cell Population
Cristina Padilla, Eleanor Valenzi, Tracy Tabib, Banafsheh Nazari, Patrizia Fuschiotti and Robert Lafyatis, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Scleroderma-associated interstitial lung disease (SSc-ILD) is the leading cause of death among SSc patients. Loss of alveolar epithelial cells (AEC) and bronchial cell hyperplasia,…
Abstract Number: 0952 • ACR Convergence 2023
Unraveling the Role of MiR-181 in Skin Fibrosis Pathogenesis by Targeting NUDT21
Tingting Mills¹, Minghua Wu², Hydia Puente³, Jerry Alonso⁴, Julio charles⁴, Maureen Mayes⁴ and Shervin Assassi⁵, ¹Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, ²Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ³UTHealth-Houston, Houston, TX, ⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁵University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: Nudix Hydrolase 21 (NUDT21, also known as CFIm25) is a master regulator of alternative polyadenylation. Previous studies have revealed that NUDT21 is significantly decreased…
Abstract Number: 0952 • ACR Convergence 2022
Pregnancy Course and Outcomes of Patients with Polymyositis and Dermatomyositis (PM/DM) in Our Institution
Rina Mino¹, Hiromi Shimada², Risa Wakiya², shusaku nakashima³, Mikiya Kato², taichi miyagi⁴, Yusuke Ushio⁵, Kanako Chujo⁶, Tomohiro Kameda² and Hiroaki Dobashi⁷, ¹Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ²Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁴Kagawa University, Kidagun, Japan, ⁵Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ⁶Kagawa University, Miki, Kita District, Kagawa, Japan, ⁷Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan
Background/Purpose: The purpose of this study is to determine the association between changes in disease activity during pregnancy and pregnancy outcome by analyzing a case…
Abstract Number: 0952 • ACR Convergence 2021
Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry
Sebastian Sattui¹, Richard Conway², Michael Putman³, Andrea Seet⁴, Kaley Beins⁵, Catherine Hill⁶, David Liew⁷, Sarah Mackie⁸, Puja Mehta⁹, Lorna Neill¹⁰, Gimena Gomez¹¹, Maria Salinas¹², Federico Maldonado¹³, Henrique Moriz¹⁴, Samia Studart¹⁵, NAFICE ARAUJO¹⁶, Ann Knight¹⁷, Davide Rozza¹⁸, Luca Quartuccio¹⁹, Maxime Samson²⁰, Stephane Bally²¹, Alexandre Maria²², Pascal Chazerain²³, Rebecca Hasseli²⁴, Ulf Müller-Ladner²⁵, Bimba Franziska Hoyer²⁶, Reinhard Voll²⁷, Rita Pinheiro Torres²⁸, Mariana Luis²⁹, Sandra Lúcia Ribeiro³⁰, Samar Al Emadi³¹, Jeffrey Sparks³², Tiffany Hsu³³, Kristin D'Silva³⁴, Naomi Patel³⁴, Leanna Wise³⁵, Emily Gilbert³⁶, Maria Valenzuela-Almada³⁷, Ali Duarte-Garcia³⁸, Manuel Ugarte-Gil³⁹, Emily Sirotich⁴⁰, Jean Liew⁴¹, Jonathan Hausmann⁴², Paul Sufka⁴³, Suleman Bhana⁴⁴, Rebecca Grainger⁴⁵, Wendy Costello⁴⁶, Lindsay Jacobsohn⁴⁷, Zara Izadi⁴, Anja Strangfeld⁴⁸, Elsa Frazão Mateus⁴⁹, Kimme Hyrich⁵⁰, Laure Gossec⁵¹, Loreto Carmona⁵², Saskia Lawson-Tovey⁵⁰, Lianne Kearsley-Fleet⁵³, Martin Schaefer⁵⁴, Milena Gianfrancesco⁴, Pedro Machado⁵⁵, Zachary Wallace³⁴, Jinoos Yazdany⁴ and Philip Robinson⁵⁶, ¹Hospital for Special Surgery, New York, NY, ²St. James's University Hospital, Dublin, Ireland, ³Medical College of Wisconsin, Brookfield, WI, ⁴University of California San Francisco, San Francisco, CA, ⁵Vasculitis Foundation, Kansas City, MO, ⁶Queen Elizabeth Hospital, Woodville, Australia, ⁷Austin Health, Heidelberg, Australia, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom, ⁹University College London, London, United Kingdom, ¹⁰PMR GCA Scotland, Perth, United Kingdom, ¹¹Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ¹²Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ¹³Sanatorio Güemes, Buenos Aires, Argentina, ¹⁴Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, ¹⁵HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, ¹⁶Instituto de ASsistencia Medica ao Servidor Publico Estadual de São Paulo, São Paulo, Brazil, ¹⁷Rheumatology, Institute of Medical Sciences, Uppsala University, Uppsala, Sweden, ¹⁸Epidemiology Research Unit, Italian Society of Rheumatology, Rome, Italy, ¹⁹Clinical Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ²⁰CHU Dijon Bourgogne, Hpital Franois Mitterrand, Dijon, Dijon, France, ²¹Nephrology and Dialysis Service, Metropole Savoie Hospital Center, Chambery, France, ²²Department of Internal Medicine and Multiorganic Diseases, Saint-Eloi University Hospital of Montpellier, Montpellier, France, ²³Department of Rheumatology and Internal Medicine, Diaconesses Croix Saint Simon Hospital, Paris, France, ²⁴Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, ²⁵JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ²⁶Universittsklinikum Schleswig-Holstein, Kiel, Germany, ²⁷Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ²⁸Rheumatology Service, Egas Moniz Hospital, Lisboa Occidental Hospital Centre, Lisbon, Portugal, ²⁹Department of Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portuga, Coimbra, Portugal, ³⁰Universidade Federal do Amazonas, Amazonas, Brazil, ³¹Hamad medical corporation, Doha, Qatar, ³²Brigham and Women's Hospital, Boston, MA, ³³Brigham and Women's Hospital, Jamaica Plain, MA, ³⁴Massachusetts General Hospital, Boston, MA, ³⁵LAC+USC/Keck Medicine of USC, Pasadena, CA, ³⁶Mayo Clinic, Jacksonville, FL, ³⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ³⁸Mayo Clinic, Rochester, MN, ³⁹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴⁰McMaster University, Hamilton, ON, Canada, ⁴¹Boston University, Boston, MA, ⁴²Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁴³HealthPartners, Eagan, MN, ⁴⁴Crystal Run Health, Montvale, NJ, ⁴⁵University of Otago, Wellington, New Zealand, ⁴⁶Irish Children's Arthritis Network, Bansha, Ireland, ⁴⁷University of California San Francisco, Antioch, CA, ⁴⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁴⁹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ⁵⁰University of Manchester, Manchester, United Kingdom, ⁵¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁵²Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ⁵³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵⁴German Rheumatism Research Center, Berlin, Germany, ⁵⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵⁶University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia
Background/Purpose: Patients with primary systemic vasculitis (PSV) and polymyalgia rheumatica (PMR) may be at high risk for poor COVID-19 outcomes due to the treatments used,…
Abstract Number: 0952 • ACR Convergence 2020
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Puja Khanna¹, Dinesh Khanna¹, Gary Cutter², Jeffrey Foster², Joshua Melnick³, Sara Jaafar¹, Stephanie Biggers², AKM Rahman², Hui-Chen Kuo², Michelle Feese² and Kenneth Saag⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham (UAB), Vestavia Hills, AL, ⁴University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].